Atom Investors LP lifted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 242.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 167,271 shares of the biopharmaceutical company’s stock after buying an additional 118,463 shares during the period. Atom Investors LP’s holdings in Pfizer were worth $4,165,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the company. Triad Wealth Partners LLC increased its holdings in Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares in the last quarter. ETF Store Inc. increased its holdings in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC increased its holdings in Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares in the last quarter. Pines Wealth Management LLC increased its holdings in Pfizer by 4.4% in the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares in the last quarter. Finally, Pathway Financial Advisers LLC increased its holdings in Pfizer by 0.9% in the 4th quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 403 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Stock Up 0.2%
Shares of Pfizer stock opened at $26.04 on Wednesday. The business has a 50-day moving average of $26.34 and a 200-day moving average of $26.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company has a market capitalization of $148.41 billion, a PE ratio of 19.88 and a beta of 0.34. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75.
Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer’s obesity pipeline gained traction after detailed Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and low reported adverse events. Pfizer has already moved the program into Phase 3, which could support longer-term growth expectations. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
- Positive Sentiment: CEO comments that Pfizer could return to high-single-digit growth suggest the business may be stabilizing faster than some investors expected, reinforcing the idea that the company’s recent weakness may be overdone. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
- Neutral Sentiment: Pfizer is drawing heavy investor interest and analyst coverage, with recent research pieces focusing on its discounted valuation, pipeline prospects, and post-COVID growth outlook. That keeps sentiment active, but the articles do not point to a single new catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
- Neutral Sentiment: Pfizer also remained in the news through broader healthcare coverage and research roundups, but these items appear informational rather than stock-moving. Top Research Reports for Pfizer, Altria & Newmont Corp.
- Negative Sentiment: Some coverage continues to frame Pfizer as a value stock facing fading COVID revenue and looming patent-cliff pressure, which reminds investors of the company’s near-term growth challenges even as pipeline efforts progress. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?
Analysts Set New Price Targets
Several brokerages recently issued reports on PFE. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. UBS Group restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Morgan Stanley raised their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.82.
Read Our Latest Analysis on PFE
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Read More
- Five stocks we like better than Pfizer
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
